Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spero Therapeutics (SPRO) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for Spero Therapeutics (SPRO) over the last 10 years, with Q3 2025 value amounting to $2.4 million.

  • Spero Therapeutics' Gains from Investment Securities fell 1597.07% to $2.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.4 million, marking a year-over-year decrease of 1597.07%. This contributed to the annual value of $2.8 million for FY2024, which is 177.08% down from last year.
  • As of Q3 2025, Spero Therapeutics' Gains from Investment Securities stood at $2.4 million, which was down 1597.07% from $2.6 million recorded in Q2 2025.
  • In the past 5 years, Spero Therapeutics' Gains from Investment Securities ranged from a high of $5.8 million in Q1 2022 and a low of $100000.0 during Q4 2022
  • Moreover, its 5-year median value for Gains from Investment Securities was $2.9 million (2023), whereas its average is $3.4 million.
  • Per our database at Business Quant, Spero Therapeutics' Gains from Investment Securities tumbled by 9795.53% in 2022 and then skyrocketed by 211100.0% in 2023.
  • Quarter analysis of 5 years shows Spero Therapeutics' Gains from Investment Securities stood at $4.9 million in 2021, then tumbled by 97.96% to $100000.0 in 2022, then surged by 2111.0% to $2.2 million in 2023, then rose by 27.31% to $2.8 million in 2024, then decreased by 14.72% to $2.4 million in 2025.
  • Its Gains from Investment Securities was $2.4 million in Q3 2025, compared to $2.6 million in Q2 2025 and $2.6 million in Q1 2025.